Financial reports
20-F
2023 FY
Annual report (foreign)
14 Mar 24
20-F
2022 FY
Annual report (foreign)
16 Mar 23
20-F
2021 FY
Annual report (foreign)
22 Mar 22
20-F
2020 FY
Annual report (foreign)
23 Mar 21
20-F
2019 FY
Annual report (foreign)
30 Mar 20
20-F/A
2018 FY
Annual report (foreign) (amended)
19 Apr 19
20-F
2018 FY
Annual report (foreign)
21 Mar 19
20-F
2017 FY
Annual report (foreign)
20 Mar 18
20-F
2016 FY
Annual report (foreign)
17 Mar 17
Current reports
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
22 Jan 24
6-K
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's diseases
3 Jan 24
6-K
Current report (foreign)
19 Dec 23
6-K
Current report (foreign)
15 Dec 23
6-K
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
1 Dec 23
6-K
Current report (foreign)
3 Nov 23
6-K
Current report (foreign)
4 Aug 23
6-K
AC Immune SA Appoints New Chief Medical Officer
26 Jul 23
6-K
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
27 Jun 23
Registration and prospectus
F-3
Shelf registration (foreign)
14 Mar 24
424B5
Prospectus supplement for primary offering
15 Dec 23
424B5
Prospectus supplement for primary offering
19 May 22
424B5
Prospectus supplement for primary offering
5 May 21
F-3
Shelf registration (foreign)
28 Apr 21
F-3
Shelf registration (foreign)
23 Oct 20
424B5
Prospectus supplement for primary offering
8 Sep 20
S-8
Registration of securities for employees
5 Aug 19
F-3
Shelf registration (foreign)
24 Aug 18
424B5
Prospectus supplement for primary offering
20 Jul 18
Proxies
No filings
Other
EFFECT
Notice of effectiveness
6 May 21
CORRESP
Correspondence with SEC
3 May 21
UPLOAD
Letter from SEC
30 Apr 21
EFFECT
Notice of effectiveness
6 Nov 20
CORRESP
Correspondence with SEC
3 Nov 20
UPLOAD
Letter from SEC
29 Oct 20
UPLOAD
Letter from SEC
25 Feb 20
CORRESP
Correspondence with SEC
17 Jan 20
UPLOAD
Letter from SEC
6 Jan 20
CORRESP
Correspondence with SEC
20 Dec 19
Ownership
SC 13G/A
AFFIRIS AG in Liqu
9 Feb 24
144
Notice of proposed sale of securities
28 Dec 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
19 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
144
Notice of proposed sale of securities
11 Dec 23
144
Notice of proposed sale of securities
6 Dec 23
144
Notice of proposed sale of securities
22 Aug 23
144
Notice of proposed sale of securities
21 Aug 23
144
Notice of proposed sale of securities
17 Aug 23
144
Notice of proposed sale of securities
9 Aug 23